ExpreS2ion Biotech Holding AB

As of June 30, 2026, ExpreS2ion Biotech Holding AB carries a market capitalization of 36.34M, placing it among publicly traded companies globally. Its enterprise value stands at 2.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ExpreS2ion Biotech Holding AB's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, ExpreS2ion Biotech Holding AB has 23.75M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.96, and the price-to-book ratio stands at 0.87.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.55M versus a market cap of 36.34M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ExpreS2ion Biotech Holding AB maintains a current ratio of 3.38, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.41, indicating moderate leverage, while an interest coverage ratio of -182.14 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, ExpreS2ion Biotech Holding AB posted a negative return on equity (ROE) of -85.17, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -54.71, reflecting losses generated across the asset base. The company generates approximately 191,850.00 in revenue per employee across its workforce of 20.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, ExpreS2ion Biotech Holding AB recorded an income tax benefit of -7.65M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -43.56M and -35.91M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, ExpreS2ion Biotech Holding AB's stock has declined approximately 84.35% over the past 52 weeks. The 50-day moving average sits at 1.21, while the 200-day moving average is 2.31.

Over the twelve months ended June 30, 2026, ExpreS2ion Biotech Holding AB generated 3.84M in revenue and converted that into -35.91M in net income, yielding earnings per share of -0.93. EBITDA reached -42.62M, while operating income came in at -43.84M.

As of June 30, 2026, ExpreS2ion Biotech Holding AB holds 34.38M in cash and equivalents against 589,000.00 in total debt, resulting in a net debt position of -33.79M. Total book value stands at 41.78M, with working capital of 35.34M providing operational flexibility.

ExpreS2ion Biotech Holding AB produced -47.77M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -307,000.00 in capital expenditures, free cash flow totaled -48.08M - equivalent to -4.84 per share.

Over the twelve months ended June 30, 2026, ExpreS2ion Biotech Holding AB posted a gross margin of 8.81, reflecting its pricing power and cost economics. The operating margin of -1,142.53 and net profit margin of -935.91 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -80.99: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -98.17, meaning ExpreS2ion Biotech Holding AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

ExpreS2ion Biotech Holding AB's most recent stock split took place on April 13, 2026.